Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders
Primary Purpose
Binge-Eating Disorder, Obesity
Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Naltrexone and Bupropion
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Binge-Eating Disorder
Eligibility Criteria
Inclusion Criteria:
- 18 to 64 years old
- Meets DSM-5 criteria for binge-eating disorder
- BMI 27-30 with a controlled obesity-related co-morbidity; or BMI ≥ 30 and <50
- Medically cleared as determined by EKG and medical record review
- Available for the duration of the treatment and follow-up (18 months)
- Read, comprehend, and write English at a sufficient level to complete study-related materials
- Able to travel to study location (New Haven, CT) for weekly visits
Exclusion Criteria:
- Previous history of problems with LDX or other stimulants
- Current psychostimulant use or use of any medication for ADHD
- Current use of study medications: LDX (Vyvanse), Bupropion (Wellbutrin, Zyban), Naltrexone, or Contrave
- History of congenital heart disease, known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, cerebrovascular pathology including stroke, exertional chest pain, uncontrolled high blood pressure, and other serious heart problems.
- History of severe renal, hepatic, neurological, or chronic pulmonary disease or other serious, unstable medical disorder.
- Current uncontrolled hypertension
- Current uncontrolled type I or II diabetes mellitus
- Current uncontrolled thyroid illness
- Gallbladder disease
- Co-occurring severe mental illness requiring hospitalization or intensive treatment
- Endorses current active suicidal or homicidal ideation with intent or plan
- History or current alcohol or substance use disorder (smoking is not exclusionary)
- Predisposition to seizures
- History of anorexia nervosa or bulimia nervosa, or currently regularly self-inducing vomiting
- Currently taking MAOI, SSRI or strong inhibitors of CYP2D6
- History of allergy or sensitivity to the study medication or stimulant medications
- Current use of medications contraindicated with the study medications
- Currently breast feeding or pregnant, or not willing to use reliable form of contraception
- Currently taking opioid pain medications or drugs
- Currently using effective treatment (evidence-based therapeutic or psychopharmacologic) for eating and/or weight loss
- Currently participating in another clinical study in which the participant is or will be exposed to an investigational or a non-investigational drug or device
- Medical status judged by study physician as contraindication
Sites / Locations
- Yale Department of PsychiatryRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Naltrexone/Bupropion
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Binge-Eating Frequency
Binge-eating frequency is a continuous variable of binge-eating episodes assessed using interview (Eating Disorder Examination interview). The Eating Disorder Examination uses a 28 day recall of eating behavior. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM -5) defines binge-eating as "eating, in a discrete period of time an amount of food that is definitely larger than most people would eat during a similar period of time and under similar circumstances and a sense of loss of control over eating during the episode." The number of episodes that meet this description will be counted and totaled.
Binge-Eating Frequency
Binge-eating frequency is a continuous variable of binge-eating episodes assessed using interview (Eating Disorder Examination interview). The Eating Disorder Examination uses a 28 day recall of eating behavior. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM -5) defines binge-eating as "eating, in a discrete period of time an amount of food that is definitely larger than most people would eat during a similar period of time and under similar circumstances and a sense of loss of control over eating during the episode." The number of episodes that meet this description will be counted and totaled.
Binge-Eating Frequency
Binge-eating frequency is a continuous variable of binge-eating episodes assessed using interview (Eating Disorder Examination interview). The Eating Disorder Examination uses a 28 day recall of eating behavior. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM -5) defines binge-eating as "eating, in a discrete period of time an amount of food that is definitely larger than most people would eat during a similar period of time and under similar circumstances and a sense of loss of control over eating during the episode." The number of episodes that meet this description will be counted and totaled.
Body Mass Index
Body Mass Index is calculated using measured height and weight (e.g., percent loss).
Body Mass Index
Body Mass Index is calculated using measured height and weight (e.g., percent loss).
Body Mass Index
Body Mass Index is calculated using measured height and weight (e.g., percent loss).
Secondary Outcome Measures
Binge-Eating Remission
Categorical: zero binges/28 days
Binge-Eating Remission
Categorical: zero binges/28 days
Binge-Eating Remission
Categorical: zero binges/28 days
Eating-Disorder Psychopathology (Continuous)
Eating-disorder psychopathology is a continuous variable as assessed by the global score of the Eating Disorder Examination/Eating Disorder Examination-Questionnaire. Scores range from 0-6 (0=no eating-disorder psychopathology; 6=severe eating-disorder psychopathology).
Eating-Disorder Psychopathology (Continuous)
Eating-disorder psychopathology is a continuous variable as assessed by the global score of the Eating Disorder Examination/Eating Disorder Examination-Questionnaire. Scores range from 0-6 (0=no eating-disorder psychopathology; 6=severe eating-disorder psychopathology).
Eating-Disorder Psychopathology (Continuous)
Eating-disorder psychopathology is a continuous variable as assessed by the global score of the Eating Disorder Examination/Eating Disorder Examination-Questionnaire. Scores range from 0-6 (0=no eating-disorder psychopathology; 6=severe eating-disorder psychopathology).
Depressive Symptoms
Depressive symptoms is a continuous variable of depressive symptomatology as assessed by the self-report measure, the Beck Depression Inventory - Second Edition. Scores range from 0-63 (0=no depressive symptoms, 63=greater depressive symptoms).
Depressive Symptoms
Depressive symptoms is a continuous variable of depressive symptomatology as assessed by the self-report measure, the Beck Depression Inventory - Second Edition. Scores range from 0-63 (0=no depressive symptoms, 63=greater depressive symptoms).
Depressive Symptoms
Depressive symptoms is a continuous variable of depressive symptomatology as assessed by the self-report measure, the Beck Depression Inventory - Second Edition. Scores range from 0-63 (0=no depressive symptoms, 63=greater depressive symptoms).
Full Information
NCT ID
NCT03946111
First Posted
April 22, 2019
Last Updated
March 8, 2023
Sponsor
Yale University
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1. Study Identification
Unique Protocol Identification Number
NCT03946111
Brief Title
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders
Official Title
Cognitive-Behavioral and Pharmacologic Treatment of Binge-Eating Disorder and Obesity
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 7, 2019 (Actual)
Primary Completion Date
July 2024 (Anticipated)
Study Completion Date
July 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yale University
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This study will test the relative efficacy and effectiveness of the combination of naltrexone and bupropion (NB) medication as a treatment for binge-eating disorder (BED) in patients with obesity. This is a controlled test of whether, amongst non-responders to acute treatments, NB medication results in superior outcomes compared with placebo.
Detailed Description
Obesity is a heterogeneous problem and research has highlighted the particular significance of a subgroup with binge-eating disorder (BED), the most prevalent formal eating disorder. Improved treatments for patients with obesity and BED are needed that can produce sustained clinical outcomes and promote weight loss. This study RCT will provide new and novel findings from a controlled test, amongst non-responders to acute treatments, whether Naltrexone/Bupropion medication results in superior and longer-term outcomes than placebo.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Binge-Eating Disorder, Obesity
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Naltrexone/Bupropion
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Naltrexone and Bupropion
Intervention Description
Participants randomly assigned to this arm will receive 12 weeks of Naltrexone and Bupropion medication.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Participants randomly assigned to this arm will receive 12 weeks of an inactive placebo.
Primary Outcome Measure Information:
Title
Binge-Eating Frequency
Description
Binge-eating frequency is a continuous variable of binge-eating episodes assessed using interview (Eating Disorder Examination interview). The Eating Disorder Examination uses a 28 day recall of eating behavior. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM -5) defines binge-eating as "eating, in a discrete period of time an amount of food that is definitely larger than most people would eat during a similar period of time and under similar circumstances and a sense of loss of control over eating during the episode." The number of episodes that meet this description will be counted and totaled.
Time Frame
From baseline interview at study enrollment to 3 months after the 12-week treatment.
Title
Binge-Eating Frequency
Description
Binge-eating frequency is a continuous variable of binge-eating episodes assessed using interview (Eating Disorder Examination interview). The Eating Disorder Examination uses a 28 day recall of eating behavior. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM -5) defines binge-eating as "eating, in a discrete period of time an amount of food that is definitely larger than most people would eat during a similar period of time and under similar circumstances and a sense of loss of control over eating during the episode." The number of episodes that meet this description will be counted and totaled.
Time Frame
From post-treatment to the 6-month follow-up
Title
Binge-Eating Frequency
Description
Binge-eating frequency is a continuous variable of binge-eating episodes assessed using interview (Eating Disorder Examination interview). The Eating Disorder Examination uses a 28 day recall of eating behavior. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM -5) defines binge-eating as "eating, in a discrete period of time an amount of food that is definitely larger than most people would eat during a similar period of time and under similar circumstances and a sense of loss of control over eating during the episode." The number of episodes that meet this description will be counted and totaled.
Time Frame
From post-treatment to the 12-month follow-up
Title
Body Mass Index
Description
Body Mass Index is calculated using measured height and weight (e.g., percent loss).
Time Frame
From baseline interview at study enrollment to 3 months after the 12-week treatment.
Title
Body Mass Index
Description
Body Mass Index is calculated using measured height and weight (e.g., percent loss).
Time Frame
From post-treatment to the 6-month follow-up
Title
Body Mass Index
Description
Body Mass Index is calculated using measured height and weight (e.g., percent loss).
Time Frame
From post-treatment to the 12-month follow-up
Secondary Outcome Measure Information:
Title
Binge-Eating Remission
Description
Categorical: zero binges/28 days
Time Frame
From baseline interview at study enrollment to 3 months after the 12-week treatment.
Title
Binge-Eating Remission
Description
Categorical: zero binges/28 days
Time Frame
From post-treatment to the 6-month follow-up
Title
Binge-Eating Remission
Description
Categorical: zero binges/28 days
Time Frame
From post-treatment to the 12-month follow-up
Title
Eating-Disorder Psychopathology (Continuous)
Description
Eating-disorder psychopathology is a continuous variable as assessed by the global score of the Eating Disorder Examination/Eating Disorder Examination-Questionnaire. Scores range from 0-6 (0=no eating-disorder psychopathology; 6=severe eating-disorder psychopathology).
Time Frame
From baseline interview at study enrollment to 3 months after the 12-week treatment.
Title
Eating-Disorder Psychopathology (Continuous)
Description
Eating-disorder psychopathology is a continuous variable as assessed by the global score of the Eating Disorder Examination/Eating Disorder Examination-Questionnaire. Scores range from 0-6 (0=no eating-disorder psychopathology; 6=severe eating-disorder psychopathology).
Time Frame
From post-treatment to the 6-month follow-up
Title
Eating-Disorder Psychopathology (Continuous)
Description
Eating-disorder psychopathology is a continuous variable as assessed by the global score of the Eating Disorder Examination/Eating Disorder Examination-Questionnaire. Scores range from 0-6 (0=no eating-disorder psychopathology; 6=severe eating-disorder psychopathology).
Time Frame
From post-treatment to the 12-month follow-up
Title
Depressive Symptoms
Description
Depressive symptoms is a continuous variable of depressive symptomatology as assessed by the self-report measure, the Beck Depression Inventory - Second Edition. Scores range from 0-63 (0=no depressive symptoms, 63=greater depressive symptoms).
Time Frame
From baseline interview at study enrollment to 3 months after the 12-week treatment.
Title
Depressive Symptoms
Description
Depressive symptoms is a continuous variable of depressive symptomatology as assessed by the self-report measure, the Beck Depression Inventory - Second Edition. Scores range from 0-63 (0=no depressive symptoms, 63=greater depressive symptoms).
Time Frame
From post-treatment to the 6-month follow-up
Title
Depressive Symptoms
Description
Depressive symptoms is a continuous variable of depressive symptomatology as assessed by the self-report measure, the Beck Depression Inventory - Second Edition. Scores range from 0-63 (0=no depressive symptoms, 63=greater depressive symptoms).
Time Frame
From post-treatment to the 12-month follow-up
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
18 to 64 years old
Meets DSM-5 criteria for binge-eating disorder
BMI 27-30 with a controlled obesity-related co-morbidity; or BMI ≥ 30 and <50
Medically cleared as determined by EKG and medical record review
Available for the duration of the treatment and follow-up (18 months)
Read, comprehend, and write English at a sufficient level to complete study-related materials
Able to travel to study location (New Haven, CT) for weekly visits
Exclusion Criteria:
Previous history of problems with LDX or other stimulants
Current psychostimulant use or use of any medication for ADHD
Current use of study medications: LDX (Vyvanse), Bupropion (Wellbutrin, Zyban), Naltrexone, or Contrave
History of congenital heart disease, known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, cerebrovascular pathology including stroke, exertional chest pain, uncontrolled high blood pressure, and other serious heart problems.
History of severe renal, hepatic, neurological, or chronic pulmonary disease or other serious, unstable medical disorder.
Current uncontrolled hypertension
Current uncontrolled type I or II diabetes mellitus
Current uncontrolled thyroid illness
Gallbladder disease
Co-occurring severe mental illness requiring hospitalization or intensive treatment
Endorses current active suicidal or homicidal ideation with intent or plan
History or current alcohol or substance use disorder (smoking is not exclusionary)
Predisposition to seizures
History of anorexia nervosa or bulimia nervosa, or currently regularly self-inducing vomiting
Currently taking MAOI, SSRI or strong inhibitors of CYP2D6
History of allergy or sensitivity to the study medication or stimulant medications
Current use of medications contraindicated with the study medications
Currently breast feeding or pregnant, or not willing to use reliable form of contraception
Currently taking opioid pain medications or drugs
Currently using effective treatment (evidence-based therapeutic or psychopharmacologic) for eating and/or weight loss
Currently participating in another clinical study in which the participant is or will be exposed to an investigational or a non-investigational drug or device
Medical status judged by study physician as contraindication
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Valentina Ivezaj, Ph.D.
Phone
203-785-7210
Email
valentina.ivezaj@yale.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carlos M Grilo, Ph.D.
Organizational Affiliation
Yale School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Yale Department of Psychiatry
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06510
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Valentina Ivezaj, Ph.D.
Phone
203-785-7210
Email
valentina.ivezaj@yale.edu
First Name & Middle Initial & Last Name & Degree
Carlos M Grilo, Ph.D.
12. IPD Sharing Statement
Learn more about this trial
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders
We'll reach out to this number within 24 hrs